Huabo Biopharm

Focus: Huabo Biopharm is a Shanghai-based biotechnology company founded in 2021, specializing in monoclonal antibodies, bispecific antibodies, and fusion proteins across oncology, immunology, and ophthalmology. The company is early-stage with a diversified pipeline but limited public financial visibility.

Oncology Immunology Ophthalmology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Huabo Biopharm

AI assessmentNot Hiring

No open roles listed right now. Follow Huabo Biopharm to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

HB0017 150mg or matching placebo

Plaque Psoriasis

Phase 1

Clinical Trials (1)

NCT05442788A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Phase 1

Help build intelligence for Huabo Biopharm

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge antibody engineering platforms (bispecific antibodies, fusion proteins) with 14 active clinical programs
Exposure to multiple high-value therapeutic areas—oncology dominates the pipeline with HB0025 in Phase 2 NSCLC and TNBC, plus Phase 3 HB0017 in psoriasis showing advancement momentum
Ground-floor opportunity at a well-capitalized Chinese biotech with Shanghai headquarters positioned to serve both domestic and global markets

Watch Out For

No active job openings currently listed, suggesting limited hiring or organizational instability for external candidates
Extremely early-stage company (founded 2021) with no disclosed revenue, funding details, or employee count—limited career infrastructure and unproven sustainability

Generated by Claude from Huabo Biopharm's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

HB0025

Tumor, Subjects

Phase 1

Clinical Trials (1)

NCT04678908A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Phase 1

HB002.1T

Solid Tumor

Phase 1

Clinical Trials (1)

NCT04802980A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor

Phase 1